Moderna Stock Leapt 4.5% After Joining S&P 500. Why Analysts Don’t Expect More Gains.

[ad_1] Text dimension Moderna’s vaccine has confirmed the worth of its mRNA know-how. Munir Uz zaman/AFP through Getty Images Biotech

Read more

Nike Earnings Beat Expectations. Why Its Stock Is Jumping.

[ad_1] Text measurement Seen by a retailer window, a Nike worker stands within the entryway of the Nike SoHo retailer

Read more

Why Moderna, Illumina, or Meituan Could Be the Next Tesla Stock

[ad_1] Baillie Gifford, the Edinburgh-based cash supervisor, has constructed a stellar funding file over greater than 110 years by separating

Read more

Why Moderna, Illumina, or China’s Meituan Could Be the Next Tesla

[ad_1] Baillie Gifford, the Edinburgh-based cash supervisor, has constructed a stellar funding file over greater than 110 years by separating

Read more

CureVac Stock Tumbles After Vaccine Failure. Why More Pain May Be Coming.

[ad_1] Text measurement An worker checked bottles of vaccine diluent at a CureVac provider in France in April. Guillaume Souvant/AFP

Read more

CureVac Started the Day Worth More Than Novavax. Then Its Vaccine News Hit.

[ad_1] Text measurement CureVac’s vaccine was 47% efficient at stopping Covid-19 signs in a trial of 40,000 volunteers. JEROEN JUMELET/ANP/AFP

Read more

Novavax Vaccine Is Real Competition for Pfizer and Moderna

[ad_1] Text dimension The Covid vaccine from Novavax is virtually as efficient as these from Pfizer/BioNTech and Moderna—however simpler to

Read more

Court upholds Houston hospital’s mandatory COVID-19 vaccination policy — workers can refuse vaccine, but ‘will simply need to work somewhere else’

[ad_1] A Texas hospital system’s mandatory COVID-19 vaccination policy for workers can stand after a federal decide on Saturday dismissed

Read more

Zoom, Lululemon, Canopy Growth, and Other Stocks for Investors to Watch This Week

[ad_1] Text dimension U.S. inventory and bond markets are closed Monday for Memorial Day. Investors will return from the lengthy

Read more

Many investors ‘will be fine’ as inflation climbs. But ‘day-to-day people’? Maybe not, investment manager says

[ad_1] Not everybody can afford to be affected person. It could be “easy for Wall Street and the Fed to

Read more